Semaglutide vs. tirzepatide: what the head-to-head data actually shows

What did @timsayedmd actually say?

Tim Sayed, MD, a board-certified plastic surgeon, ran through a quick pros-and-cons list comparing semaglutide and tirzepatide. His core claims: semaglutide is cheaper ("$500 or less a month"), tirzepatide causes more nausea and GI side effects, semaglutide causes less hair shedding, and tirzepatide patients "lose a little bit more weight per month on average." He framed it as a practical comparison for patients deciding between the two.

Worth noting upfront: he is a plastic surgeon, not an endocrinologist or obesity medicine specialist. That does not automatically make him wrong, but it is relevant context when evaluating clinical claims about metabolic medications. He did not cite a single study. He offered no nuance on dosing, patient population, or how these comparisons were derived.

Does the science back this up?

Partially. The weight loss comparison holds up reasonably well. The nausea claim is backwards. The hair loss claim has some support but is more complicated than he made it sound.

On weight loss: The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at its highest dose (15 mg) produced mean weight loss of about 22.5% of body weight over 72 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg produced about 14.9% weight loss over 68 weeks. So yes, tirzepatide tends to outperform on weight reduction, though these are different trials with different populations, not a head-to-head.

On nausea: He said patients are "less likely to experience nausea and GI effects" on tirzepatide compared to semaglutide. The actual data does not support that framing. In SURMOUNT-1, nausea was reported in roughly 30-35% of tirzepatide patients. STEP 1 showed similar rates for semaglutide. A 2023 network meta-analysis (Lin et al., Diabetes, Obesity and Metabolism) found no statistically significant difference in GI tolerability between the two drugs at therapeutic doses.

What did they get wrong (or right)?

The nausea claim is the clearest error here. Saying tirzepatide is easier on the stomach than semaglutide is not supported by the clinical literature. This is a common misconception, possibly driven by anecdote or patient self-report bias, but it should not be stated as fact.

The hair loss claim is murkier. There is no strong clinical trial data showing semaglutide causes significantly more hair shedding than tirzepatide. What we do know is that rapid weight loss itself, regardless of the drug, triggers telogen effluvium, a form of stress-induced shedding. Attributing this to the drug rather than the weight loss trajectory is misleading. Both drugs can cause hair shedding indirectly through the same mechanism.

He did get the weight loss comparison directionally right. Tirzepatide's dual GIP and GLP-1 agonism does appear to drive greater average weight reduction. And the price point for semaglutide being more accessible is generally accurate in the compounded market, though he did not distinguish between branded and compounded versions, which matters legally and clinically.

What should you actually know?

These are not interchangeable drugs with one obvious winner. Tirzepatide (Zepbound, Mounjaro) targets both GLP-1 and GIP receptors. Semaglutide (Wegovy, Ozempic) targets GLP-1 only. The dual mechanism of tirzepatide likely explains its superior weight loss outcomes, but superior average results in a trial population do not guarantee superior results for any individual patient.

Side effect profiles are more similar than different. Both drugs carry risks of nausea, vomiting, constipation, and gastroparesis with longer use. The FAERS database and post-market surveillance data show comparable GI adverse event rates across both agents. Choosing one over the other based on GI tolerability alone is not well-supported by evidence.

Cost is genuinely complicated. Brand-name tirzepatide and semaglutide both carry list prices well above $500 per month without insurance. Compounded versions are cheaper but are not FDA-approved and cannot be claimed as equivalent to brand-name products. Anyone making a cost comparison should be transparent about whether they mean branded or compounded formulations.

Bottom line

Sayed gets credit for flagging that tirzepatide tends to produce more weight loss and that semaglutide is more accessible on price. But the nausea claim is wrong by the current literature, and the hair loss framing oversimplifies a phenomenon driven primarily by weight loss rate, not the specific drug. A 60-second TikTok from a plastic surgeon is not the place to make this decision. Talk to a prescriber who specializes in obesity medicine or endocrinology.